- $13.94bn
- $13.16bn
- $1.16bn
- 97
- 12
- 84
- 69
2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 431 | 546 | 704 | 929 | 1,159 |
Cost of Revenue | |||||
Gross Profit | 324 | 417 | 576 | 757 | 936 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 504 | 718 | 612 | 848 | 1,060 |
Operating Profit | -72.7 | -172 | 91.9 | 81.3 | 98.7 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -140 | -219 | 77.9 | 71.7 | 90 |
Provision for Income Taxes | |||||
Net Income After Taxes | -116 | -414 | 75.7 | 52.5 | 108 |
Net Income Before Extraordinary Items | |||||
Net Income | -116 | -414 | 75.7 | 52.5 | 108 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -116 | -414 | 75.7 | 52.5 | 108 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.369 | -1.47 | 0.264 | 0.18 | 0.357 |